Previous Close | 1.1200 |
Open | 1.0900 |
Bid | 1.2000 x 100 |
Ask | 1.2000 x 100 |
Day's Range | 1.0817 - 1.2550 |
52 Week Range | 0.6100 - 12.5000 |
Volume | |
Avg. Volume | 54,216 |
Market Cap | 6.311M |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -10.3000 |
Earnings Date | Aug 11, 2024 - Aug 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.00 |
We feel now is a pretty good time to analyse Biofrontera Inc.'s ( NASDAQ:BFRI ) business as it appears the company may...
The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalpBiofrontera launched the commercial distribution of the RhodoLED XL on June 10, 2024, shipping the first three machines within 1 week of launch WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commerc
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic ...